PRDX1 is a Tumor Suppressor for Nasopharyngeal Carcinoma by Inhibiting PI3K/AKT/TRAF1 Signaling.

Xiao, Hongmei; Yang, Taoyu; Yan, Lingli; Feng, Jihong; Huang, Boyan; Jiang, Yu.

Afiliação

Xiao H; Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China.
Yang T; Oncology Department, Affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China.
Yan L; Department of Invasive Technology, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan 511500, People's Republic of China.
Feng J; Department of Immunology, Medical University, Zunyi 563000, Guizhou, People's Republic of China.
Huang B; Department of Oncology, Taizhou City People's Hospital, Taizhou 318000, People's Republic of China.
Jiang Y; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518000, People's Republic of China.

Onco Targets Ther ; 13: 9123-9133, 2020.

Article em En | MEDLINE | ID: mdl-32982301